OTLK Shares -14.6% on 104M Volume After $0.01 EPS Miss
Finance and markets: Oncobiologics missed EPS by $0.01 and reported $0.01M revenue, yet 104M shares traded (6x volume) as insiders bought $5.16M; Galectin missed by $0.05.
Finance entity
All 1 tracked stories fall under one category: earnings. Of the tracked stories, 1 of 1 also mention Galectin Therapeutics, Inc., the most common co-covered peer. Their average consequence score of 5 runs below the beat's 5.5 for that window.
Last mentioned: 2h ago
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
All 1 tracked stories fall under one category: earnings. Of the tracked stories, 1 of 1 also mention Galectin Therapeutics, Inc., the most common co-covered peer. Their average consequence score of 5 runs below the beat's 5.5 for that window. Each story carries 2 original sources on average, compared with 2.1 for the broader beat in this window. We currently track 1 Finance story that mention Faisal Ghiath Sukhtian, all published on August 16, 2026.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 32 Finance stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Faisal Ghiath Sukhtian. Shared-story counts are live from our verified record — not editorial picks.
Finance and markets: Oncobiologics missed EPS by $0.01 and reported $0.01M revenue, yet 104M shares traded (6x volume) as insiders bought $5.16M; Galectin missed by $0.05.
Faisal Ghiath Sukhtian is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.